Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate HighlightsBusiness Wire • 04/27/22
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingBusiness Wire • 04/21/22
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye DiseaseBusiness Wire • 04/05/22
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development DayBusiness Wire • 03/29/22
Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsBusiness Wire • 03/17/22
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare ConferenceBusiness Wire • 03/14/22
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate HighlightsBusiness Wire • 03/10/22
Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis PigmentosaBusiness Wire • 03/08/22
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare ConferenceBusiness Wire • 02/10/22
Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model.Benzinga • 02/01/22
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber ModelBusiness Wire • 02/01/22
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®Business Wire • 01/11/22
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual ConferenceBusiness Wire • 01/06/22
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative VitreoretinopathyBusiness Wire • 01/04/22
Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In ReproxalapSeeking Alpha • 12/23/21
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye DiseaseBusiness Wire • 12/20/21
Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't?Zacks Investment Research • 12/15/21